Rapport Therapeutics
rapportrx.com
Medical AI
Biotechnology
Health Care
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Rapport Therapeutics: Great CNS Science, But The Valuation Prices In Significant Success
Rapport Therapeutics
Read more
Report
Rapport Therapeutics Hits New 52-Week High As RAP-219 Advances Into Phase 3
Rapport Therapeutics (RAPP) touched a new 52-week high as its lead candidate RAP-219 advanced into Phase 3 trials for focal onset seizures. The company also expects Phase 2 bipolar mania data in October 2026.
Read more
Report
Is Rapport Therapeutics, Inc. (RAPP) A Good Stock To Buy Now?
Is RAPP a good stock to buy? We came across a bullish thesis on Rapport Therapeutics, Inc. on TradersPro's Substack. In this article, we will summarize the bulls' thesis on RAPP. Rapport Therapeutics, Inc.'s share was trading at $38.26 as of June 15th. RA
Read more
Report
Report
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (
Read more
Report
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million?
Read more
Report
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures
--Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced new data and post hoc analysis o
Read more
Report
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
--Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the second
Read more
Report